BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 10385666)

  • 1. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.
    Everson GT; Jensen DM; Craig JR; van Leeuwen DJ; Bain VG; Ehrinpreis MN; Albert D; Joh T; Witt K
    Hepatology; 1999 Jul; 30(1):271-6. PubMed ID: 10385666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
    Tong MJ; Reddy KR; Lee WM; Pockros PJ; Hoefs JC; Keeffe EB; Hollinger FB; Hathcote EJ; White H; Foust RT; Jensen DM; Krawitt EL; Fromm H; Black M; Blatt LM; Klein M; Lubina J
    Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
    Keeffe EB; Hollinger FB
    Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.
    Lau DT; Kleiner DE; Ghany MG; Park Y; Schmid P; Hoofnagle JH
    Hepatology; 1998 Oct; 28(4):1121-7. PubMed ID: 9755252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
    Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
    J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
    Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group.
    Keeffe EB; Dusheiko GM; Tong MJ; Hollinger FB; Heathcote EJ; McHutchison J; Albert D
    Cytokines Cell Mol Ther; 1999 Dec; 5(4):211-6. PubMed ID: 10850385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group.
    Farrell G; Cooksley WG; Dudley FJ; Watson K
    J Viral Hepat; 1997 Sep; 4(5):317-23. PubMed ID: 9310930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
    Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
    Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group.
    Heathcote EJ; James S; Mullen KD; Hauser SC; Rosenblate H; Albert DG
    Hepatology; 1999 Aug; 30(2):562-6. PubMed ID: 10421669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group.
    Lee WM; Reddy KR; Tong MJ; Black M; van Leeuwen DJ; Hollinger FB; Mullen KD; Pimstone N; Albert D; Gardner S
    Hepatology; 1998 Nov; 28(5):1411-5. PubMed ID: 9794929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFN-alpha receptor mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy.
    Mathai J; Shimoda K; Banner BF; Mori M; Bonkovsky HL; Barnard GF
    J Interferon Cytokine Res; 1999 Sep; 19(9):1011-8. PubMed ID: 10505743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group.
    Jensen DM; Krawitt EL; Keeffe EB; Hollinger FB; James SP; Mullen K; Everson GT; Hoefs JC; Fromm H; Black M; Foust RT; Pimstone NR; Heathcote EJ; Albert D
    Am J Gastroenterol; 1999 Dec; 94(12):3583-8. PubMed ID: 10606323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C.
    Hwang SJ; Lee SD; Chan CY; Lu RH; Chang FY
    Am J Gastroenterol; 1999 Sep; 94(9):2496-500. PubMed ID: 10484014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon.
    Reichard O; Glaumann H; Frydén A; Norkrans G; Wejstål R; Weiland O
    J Hepatol; 1999 May; 30(5):783-7. PubMed ID: 10365802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose.
    Shiffman ML; Hofmann CM; Luketic VA; Sanyal AJ; Contos MJ; Mills AS
    Hepatology; 1996 Jul; 24(1):21-6. PubMed ID: 8707264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.